Fecal immunochemical test screening may impact colorectal cancer surgery rates
the ONA take:
Screening based on fecal immunochemical testing (FIT) may have an impact on both proximal and distal colorectal cancer (CRC) surgery rates, according to an Italian study published online ahead of print inCancer.
Researchers led by Ugo Fedeli, MD, of the Regional Epidemiological Department categorized patients with CRC in the Veneto region of Italy based on staggered introduction of FIT-based screening programs: early (2002 to 2004), intermediate (2005 to 2007), and late (2008 to 2009).
Proximal and distal CRC surgery rates were investigated in these three populations between 2001 and 2012 through Joinpoint regression analysis and segmented Poisson regression models.
The researchers found that impact of screening was similar in study populations. Distal CRC surgical resection rates were found to be stable before screening, increased at time of screening implementation, and declined afterward by 10 percent annually.
Proximal CRC surgical resection rates increased by four percent annually before screening, but after a peak with screening initiation had reversed thereafter. In addition, the percentage represented by proximal CRC surgery rose from 28 percent in 2001 to 41 percent in 2012.They concluded that their “findings across each time series demonstrated that FIT-based screening programs have an impact on proximal and distal CRC surgery rates. “ However, they also noted that “underlying preexisting epidemiological trends are leading to a rapidly increasing percentage of proximal CRC.”
Screening based on fecal immunochemical testing (FIT) may have an impact on both proximal and distal colorectal cancer (CRC) surgery rates.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|